Ductal carcinoma in situ (DCIS) of the breast has become increasingly important as a result of breast screening, now accounting for approximately 20% of screening detected breast cancers. Previous studies of ER (oestrogen receptor) expression in pure DCIS have been limited (Barnes & Masood, 1990; Bur et al., 1992; Giri et al., 1989; Malafa et al., 1990; Ronay et al., 1990 ) and of smaller size. Results of ER status in DCIS in the literature have often been described as a part of much larger series of symptomatic invasive breast tumours. Previous studies have indicated that positive ER status in DCIS is associated with certain morphological subtypes of in situ mammary carcinoma (Barnes & Masood, 1990; Bur et al., 1992; Giri et al., 1989) .
The management of DCIS is now the subject of several ongoing clinical trials in Europe and the USA, some of which include endocrine therapy as part of trial protocols (Fentiman, 1990; 1992) . Positive ER status in DCIS could infer a possible survival advantage or a relatively lower degree of biological tumour aggressiveness, and might also predict response to hormonal therapy Robertson et al., 1992) , in particular to tamoxifen. ER is a nuclear protein which shows sequence specific transcription regulatory activity. Recent studies have also shown that in the absence of a ligand the human ER has both constitutive activator and repressor functions. In the absence of ligand ER can bind and repress activators of the oestrogen response element of the ER gene (Tzukerman et al., 1990) .
ER expression has been extensively investigated in invasive breast carcinoma by radioligand binding assay techniques such as dextran coated charcoal assay (DCC), and sucrose density gradient centrifugation, and more recently by techniques such as the immunohistochemical oestrogen receptor assay (ERICA) (Charpin et al., 1986; Nicholson et al., 1991; Remmele et al., 1986; Robertson et al., 1992; Snead et al. (in press) ; Walker et al., 1988) . The development of ERICA assays has been facilitated by the availability of well characterised monoclonal antibodies to the ER protein. techniques (Charpin et al., 1986; Remmele et al., 1986; Walker et al., 1988) .
Recently, utilising an enzyme pre-digestion step prior to incubation with monoclonal anti-ER antibody, expression of ER protein has been demonstrated in archival formalin-fixed paraffin-embedded breast tumour tissue with comparable results to ERICA performed on frozen sections of breast tumour tissue stored at -20°C, ER radioligand assays, or immunoassays (Aasmundstad et al., 1992; Cheng et al., 1988; Elias et al., 1990; Graham et al., 1991; Paterson et al., 1990; Raymond & Leong, 1990; Snead et al. (in press); Wilbur et al., 1992) .
Pronase pre-digestion of tissue sections was utilised in many of the studies of ER expression in formalin-fixed paraffin-embedded breast tumour tissue to date (Aasmundstad et al., 1992; Cheng et al., 1988; Graham et al., 1991; Raymond & Leong, 1990; Snead et al. (in press) ). One study employed pronase pre-digestion with repeated applications of primary antibody (Elias et al., 1990) . Equivalent results have also been claimed for ERICA techniques applied to formalinfixed paraffin-embedded tissue that use DNase pre-digestion of tissue sections (Paterson et al., 1990; Shintaku & Said, 1987) or protease pre-digestion (Barnes & Masood, 1990) .
The presence of oestrogen receptor expression in invasive breast carcinoma has been shown in some series to be associated with low tumour grade, i.e. well differentiated tumours (Walker et al., 1988) . Positive ER status also tends to predict a greater likelihood of response to endocrine therapy Robertson et al., 1992) Immunocytochemistry (ERICA) Representative blocks of formalin-fixed paraffin-embedded tumour tissue from cases of symptomatic or screening detected DCIS were taken and sections cut at 3 jim. The sections were dewaxed in xylene and graded alcohol/water mixtures and then immersed in a 0.5% hydrogen peroxide/ methanol mixture for 1 min to block endogenous peroxidase activity. Pronase pre-digestion of tumour sections was then performed by applying 0.02% pronase [Sigma P-691 1] in 0.1 M phosphate buffered saline (PBS) at 37°C for 9 min using a modification of the method first described by Cheng et al. (1988) .
After washing in running tapwater and rinsing in Tris buffered saline (TBS) at pH 7.6, 1/5 normal swine serum in TBS was then applied for 10 min to block non-specific binding sites of the anti-oestrogen receptor antibody, followed by overnight incubation with primary anti-ER antibody (Abbott H222, Abbott Ltd, Maidenhead, Berks, UK) diluted in equal volumes with TBS, at room temperature, with a secondary biotinylated sheep anti-rat antibody (Amersham RPN 1002, Amersham, Bucks, UK) at a dilution of 1/100 in normal swine serum/TBS for 30 min. An avidin-biotin immunoperoxidase complex (ABC complex) was then utilised (Dako Ltd, High Wycombe, Bucks, UK) with diaminobenzidine as a chromogen (Abbott, Abbott Ltd, Maidenhead, Berks, UK). Post-intensification was then performed with 0.5% copper sulphate in 0.8% NaCl for 10 min. Sections were counterstained with ethyl green solution. The above method used on formalin-fixed paraffin-embedded tumour tissue had been previously shown in our laboratory to give optimal results and correlation with ERICA examination of frozen tissue sections in a series of 94 invasive breast carcinomas (Snead et al., in press), drawn from the Nottingham/Tenovus Primary Breast Carcinoma Series (Todd et al., 1987) . Similar results with pronase pre-digestion have also been obtained by others (Aasmundstad et al., 1992; Wilbur et al., 1992 (Pertschuk et al., 1985) . (1985) , as previously described (Locker et al., 1990) . The DNA index and S-phase fraction (S-pf) were derived. Histograms were considered interpretable if the coefficient of variation was less than or equal to 8%. The DNA index was calculated by measuring the ratio of the mode of the GO/GI peak of the sample divided by the mode of the relative DNA measurement of diploid GO/GI cells present in the sample. The S-phase fraction was calculated using a modification of the method of Baisch et al. (1975) . Tumours were classified as aneuploid if the DNA index was greater than or equal to 1.15. Tumours with a DNA index less than 1.15 were considered to be diploid. c-erbB-2 overexpression Overexpression of the c-erbB-2 oncoprotein was asssessed using the affinity purified antibody 21N, a generous gift of Dr W.J. Gullick, ICRF Molecular Oncology Group, London, England. The antibody binds residues 1243-1255 of the predicted amino acid sequence of the c-erbB-2 protein (Venter et al., 1987) . The tumours were stained with appropriate controls as previously described (Lovekin et al., 1991) . Positive membrane immunoreactivity indicated c-erbB-2 overexpression. Tumours that showed heterogenous membrane c-erbB-2 staining were regarded as c-erbB-2 positive for the purposes of statistical analysis. Some cases showed weak cytoplasmic staining with 21N, but this was ignored for the purposes of further analysis.
Results
Oestrogen receptor immunocytochemical assay (ERICA) One hundred and fifty-one cases of pure DCIS were examined. Some tumours showed positive nuclear ER staining of surrounding normal breast ducts and acini, as well as of neoplastic breast tissue. A case of DCIS of comedo architecture showing typical positive nuclear ER staining is shown in Figure 1 Table IV ).
S-phase fraction S-pf could be derived from the DNA histograms in 80 cases. Taking an arbitrary cut-off of 6%, with subdivision of the tumours into two groups, 40 tumours had an S-phase fraction less than 6% and 40 tumours S-pf greater than 6%. A positive statistical association of higher S-phase and positive ER status was identified, x2 = 4.71; (d.f. = 1): P = 0.03 in the subgroup of tumours with S-pf greater than 6% (please see Table IV ). As ER expression is also present in benign mammary epithelial tissue, the presence of significant ER receptor expression in benign breast tissue adjacent to invasive tumours which in some cases are ER negative (Walker et al., 1992) could be a potential cause some false positive biochemical ER assay results.
Our finding of a relatively lower frequency of ER expression in comedo and large cell DCIS as compared to small cell DCIS is consistent with three earlier studies (Barnes & Masood, 1990; Bur et al., 1992; Giri et al., 1989) . Barnes and Masood (1990) (Ronay et al., 1990) .
The largest series of ER in DCIS published to date (Bur et al., 1992) (Nowell, 1976) . No significant associations of ER expression and DNA aneuploidy could be identified in our study. There was a significant association of higher S-phase fraction and positive ER status, this is difficult to explain, given our current knowledge of the biology of breast cancer. No other study has examined the relationship of ER and DNA flow cytometry in DCIS to our knowledge. We noted a similar inverse relationship of positive ER status and absence of c-erbB-2 overexpression in DCIS, as has also been described by ourselves and others in invasive breast carcinoma (Lovekin et al., 1990 (Fentiman, 1992) and the USA.
It is likely, however, that the mechanisms controlling oestrogen receptor mediated signal transduction are complex, and that the absence of immunohistochemically detectable ER may not necessarily preclude patient response to endocrine therapy in some instances, as is the case in invasive breast carcinoma.
Comedo DCIS and subtypes of DCIS showing significant tumour cell necrosis have been shown to have a shorter time to local recurrence after breast conservation treatment. Comedo DCIS and large cell DCIS have a relatively lower frequency of ER expression than small cell DCIS. Comedo DCIS has a higher cellular proliferation fraction as measured by thymidine labelling index (TLI) (Meyer, 1986) , or flow cytometric S-phase fraction (Locker et al., 1990) . Comedo DCIS shows c-erbB-2 oncoprotein overexpression in a higher proportion of cases than non-comedo DCIS ( Van de Viijver et al., 1988; Locker et al., 1990) . The confirmation of a relatively higher frequency of ER expression in small cell DCIS and the same inverse relationship of lack of ER expression and c-erbB-2 protein overexpression in DCIS as seen in invasive breast carcinoma suggests evidence for homology of ER and c-erbB-2 protein expression in both forms of mammary carcinoma. This latter relationship appears conserved in neoplastic progression from in situ to invasive disease. This study addresses one major aspect of ER in DCIS; namely the immunohistochemical expression of oestrogen receptor. Subsequent prospective studies of ER status in DCIS should also take account of the menopausal status of patients, and the role of timing of surgery within the menstrual cycle, both of which may possibly influence the ER status of invasive breast tumours and their response to treatment. This data was not available in our retrospective series. The lower frequency of ER expression in pure DCIS as compared to that in invasive disease may provide an avenue for investigation of the function of oestrogen receptor in the neoplastic progression of mammary carcinoma from in situ to invasive malignancy.
